Loading
Vetoquinol SA Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest was filed 03 Jul 2026.
Vetoquinol SA: what insiders have been doing
This page follows insider dealings at Vetoquinol SA as filed with AMF, a company from the Healthcare & Pharma sector. 3 insiders have disclosed 4 filings since 18 October 2025.
Both sides are active: 3 purchases worth €237k and 1 sale worth €70k, from 2 insiders and 1 insider respectively. Purchases outweigh sales by €167k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The largest single trade was a purchase of €96k by Soparfin SCA SCA, published on 2 February 2026.
Within a 30-day window, 1 purchase overlapped with buying by a second insider. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The most recent open-market purchase was published on 3 July 2026, 106 days ago. The median gap between a trade and its publication by AMF is 2 days. The regulation allows three business days to notify a trade (MAR article 19).
Across the 316 companies tracked on its exchange, the median is 6 filings; at 4 filings, this issuer sits below that mark. Since 2021, the database holds 20 purchases and 14 sales by insiders of the company.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from AMF disclosures alone and does not predict where the share price will go.
Insider Decl.
36
Thresholds
n/a
Buy Volume
€5M
20 ops. · all time
Sell Volume
€3M
14 ops. · all time
Who traded when
BuySaleSoparfin SCA SCA4 buys
Bénédicte LEURS1 buy2 sales
Lustah SAS SAS2 buys1 sale
Since the insiders bought
- +8.0%Entry €71.60 · Close 14 Oct 2026 €77.30
- +9.2%Entry €70.80 · Close 14 Oct 2026 €77.30
- -6.7%Entry €78.00 · Close at T+365 €72.80
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Fundamental score
Ranked 2,200 of 24,148 companies
74.7
score / 100
Value71
Quality79
FCF yld5.7%
Earn yld6.3%
EV/EBITDA8.0x
ROE11%
Gross mgn75%
Net mgn11%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€78.10
Analyst consensus
4 analysts1.50/5
€80.00Target €91.50(+17%)€110.00
Income statement
Revenue€525.7M
Gross profit€392.8M75% margin
EBITDA€116.0M22% margin
Net income€57.4M11.9% margin
Valuation
PER (trailing)14.4x
PER (forward)13.7x
P/Book1.5x
Beta0.83
Balance sheet & cash
Market cap€907.9M
Total debt€15.3M
Free Cash Flow€51.3M
Debt / Equity2%
Profitability & ownership
ROE10.7%
ROA7.0%
% insiders67.0%
% institutions12.8%
Last declaration on 3 July 2026
Declarations36 total
1,000 shares@ €71.150.0081% mcap9.9% of flowActionde gré à gréISIN FR00041868562026DD1124656
Canonical exit: 29 Sept 2026 (T+90)
1,000 shares@ €69.500.0082% mcap1.8% of flowActionde gré à gréISIN FR00041868562026DD1121792
Canonical exit: 15 Sept 2026 (T+90)
1,000 shares@ €69.500.0082% mcap2.8% of flowActionde gré à gréISIN FR00041868562026DD1121794
1,111 shares@ €86.502.5% of flowActionde gré à gréISIN FR00041868562026DD1092303
Canonical exit: 30 Apr 2026 (T+90)
4,930 shares@ €75.0014.9% of flowActionde gré à gréISIN FR00041868562025DD1047066
Canonical exit: 5 Oct 2025 (T+90)
4,930 shares@ €75.0051.7% of flowActionde gré à gréISIN FR00041868562025DD1047067
3,500 shares@ €78.4011.0% of flowActioncession de gré à gréISIN FR00041868562025DD1029915
3,500 shares@ €78.4038.4% of flowActionacquisition de gré à gréISIN FR00041868562025DD1029919
Canonical exit: 2 Jul 2025 (T+90)
2,000 shares@ €75.003.9% of flowActionacquisition de gré à gréISIN FR00041868562025DD1015324
Canonical exit: 13 Apr 2025 (T+90)
1,535 shares@ €84.003.4% of flowActionacquisition de gré à gréISIN FR00041868562024DD1007961
Canonical exit: 20 Feb 2025 (T+90)
500 shares@ €85.901.1% of flowActionacquisition de gré à gréISIN FR00041868562024DD999981
Canonical exit: 6 Jan 2025 (T+90)
4,000 shares@ €99.9010.5% of flowActionacquisition de gré à gréISIN FR00041868562024DD988655
Canonical exit: 23 Oct 2024 (T+90)
4,000 shares@ €99.9016.1% of flowActioncession de gré à gréISIN FR00041868562024DD988658
3,500 shares@ €99.0013.9% of flowActionDe gré à gréISIN FR00041868562024DD956882
3,500 shares@ €99.009.1% of flowActionDe gré à gréISIN FR00041868562024DD956883
Canonical exit: 19 Jun 2024 (T+90)
1,800 shares@ €101.604.8% of flowActionacquisition de gré à gréISIN FR00041868562024DD944555
Canonical exit: 2 Apr 2024 (T+90)
1,000 shares@ €87.503.5% of flowActionCession de gré à gréISIN FR00041868562023DD938591
1,000 shares@ €87.502.3% of flowActionacquisition de gré à gréISIN FR00041868562023DD938592
Canonical exit: 14 Feb 2024 (T+90)
400 shares@ €84.900.9% of flowActionacquisition de gré à gréISIN FR00041868562023DD927755
Canonical exit: 7 Dec 2023 (T+90)
1,500 shares@ €89.403.5% of flowActionacquisition de gré à gréISIN FR00041868562023DD878664
Canonical exit: 2 Apr 2023 (T+90)
5,500 shares0ActionHors plateforme de négociationISIN FR00041868562022DD844237
3,500 shares@ €129.5011.9% of flowActionAcquisition de gré à gréISIN FR00041868562022DD823744
Canonical exit: 22 May 2022 (T+90)
100 shares@ €126.6018.1% of flowActionEuronext ParisISIN FR00041868562022DD821285
130 shares@ €133.0024.7% of flowActionEuronext ParisISIN FR00041868562022DD821286
1,500 shares@ €132.005.2% of flowActionEuronext ParisISIN FR00041868562022DD814521
25 of 36 declarations
About Vetoquinol SA
Vetoquinol SA is an independent veterinary pharmaceutical company focused on animal health. Listed on Euronext Paris since 2006 under the ticker VETO, the group serves two main end markets: companion animals, especially dogs and cats, and farm animals, notably cattle and pigs. Its business model covers the research, development, manufacturing and marketing of veterinary medicines as well as non-medicated products used to prevent, treat or support animal health conditions. In 2025, the company generated annual sales of €525.7 million, with a significant contribution from its Essentials portfolio, which has become a strategic engine for growth and profitability. Vetoquinol is therefore one of the leading international players in animal health, with operations across Europe, the Americas and Asia-Pacific.
The company’s history dates back to 1933, when Joseph Frechin founded Vetoquinol in Lure, in eastern France. Since its origins, the group has followed a specialization strategy built around independence, scientific expertise and a strong veterinary focus. This family-rooted entrepreneurial background remains a core differentiator compared with many peers that are part of larger diversified pharmaceutical groups. Over time, Vetoquinol has expanded through a combination of targeted acquisitions, product innovation and international development, building a portfolio that is well established among veterinarians and animal owners.
Read moreShow less
Vetoquinol markets solutions across several key therapeutic areas, including anti-infectives, anti-inflammatories, dermatology, pain management, locomotion, parasitology, reproduction and supportive care. The company addresses the everyday needs of veterinarians while also serving breeders and pet owners. A central pillar of the strategy is the “Essentials” category, made up of core products with strong recurring demand and potential to become market leaders. This segment supports revenue visibility and reflects the group’s emphasis on products with durable demand and broad clinical relevance. Vetoquinol also stands out for its commitment to innovation, customer proximity and local adaptation through a network of subsidiaries and distributors.
Geographically, the group benefits from a diversified footprint that reduces exposure to any single market and helps balance business cycles across regions. This international presence supports resilience and provides access to markets with varying growth dynamics. Notable facts about Vetoquinol include its long operating history of more than 90 years, its status as a pure-play animal health specialist, and its position among the top global players in its industry. The company’s profile is also underpinned by favorable structural trends, such as rising veterinary care spending, increased pet ownership and the ongoing professionalization of livestock health management.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
